

For further Information contact:
Rob Harris, PhD.
President/CSO
Commonwealth Biotechnologies, Inc.
804-648-3820

Commonwealth Biotechnologies, Inc. Reports 2001 Financial Outcome

RICHMOND, VA (April 1, 2002) - Commonwealth Biotechnologies, Inc. (NASDAQ: CBTE), a life sciences contract research organization and biotechnology company, reports an operating loss of \$1,673,031 for 2001 on gross revenues of \$4,786,087. While gross revenues for 2001 were up \$ 419,128 from \$4,366,959, an increase of 9.6% compared to 2000, CBI shareholders suffered a loss of \$ 0.81 per share (basic and diluted) of common stock.

"This has been a difficult year for CBI", said Richard J. Freer, Chairman of the Company and COO. "While our expectations entering 2001 were optimistic, the poor performance of the economy in general, and the downturn in the biotechnology sector in particular, caused a number of our clients to either cancel or delay outsourcing of their projects to us. The company has responded to these circumstances by reducing its workforce by 30%, deferring significant management compensation and all board compensation, and minimizing all non-production expenditures and material purchases. Furthermore, management has redoubled its efforts to increase top line revenues, which is how this problem ultimately must be solved."

"While our overall performance was disappointing in 2001, there were some notable achievements," said Dr. Robert B. Harris, President and CSO. "The company showed very significant growth (>49%) in its prime revenue target, long-term, project-based commercial clients. Just recently, we announced execution of a two-year research agreement with Insmed Inc., another Richmond-based firm, to provide them with fundamental research and clinical support services. Furthermore, CBI believes it is

recognized in the bio-defense community for its expertise in addressing problems related to detection and analysis of biowarfare agents, and the company was the recipient of significant contracts related to these activities in 2001. CBI is also competing for new contracts in this area, either as prime contractor or teamed with other major defense contractors. It is management's belief that long-term contractual clients will serve to remedy our profit shortfalls."

In 2001, CBI underwent extensive internal strategic review of its platform technologies to identify those which were not contributing to the overhead and profit margins of the company. As a result, several technology platforms were re-priced and some were eliminated all together. The review also extended to CBI's fiscal practices and strategic direction, and as a consequence, CBI re-organized and assigned some of the current duties and responsibilities of senior management to various senior scientific staff members. These moves have allowed senior management to take a more active role in the early interactions with potential clients with a view towards development of new business opportunities.

"CBI management is keenly aware of the need to continuously streamline its operations while maintaining its competitive edge," added Harris. "We are moving forward with a bottom-line mentality and are focusing the company's efforts and energies on becoming profitable."

In other recent news, the company announced licensing of two of its intellectual properties, HepArrest™ and AccuTrac™. HepArrest was licensed to MediRox, Linkoping, Sweden for use in MediRox's proprietary *in vitro* blood coagulation test and AccuTrac was licensed to Applied Biosystems, Inc. Foster City, CA and The Gel Company, San Francisco, CA for sale and distribution as a DNA sequencing aid.

About CBI

Founded in 1992, CBI is located at 601 Biotech Drive, Richmond, VA 23235 (1-800-735-9224). The company occupied its 32,000 square foot facility in December, 1999. CBI has provided comprehensive research and development services to more than 2,500 private, government, and academic customers in the global biotechnology industry. For more information, visit CBI on the web at www.cbi-biotech.com.

#

Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in the company's filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. No statement herein should be considered an offer of any securities. Such an offer can only be made in accordance with federal and applicable state securities laws. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof. Specifically, there can be no guarantee that (i) CBI will achieve profitability or (ii) CBI will record any significant revenues or profits from the licensing of HepArrest or AccuTrac. The company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

#